CryoPort (CYRX) Stock Forecast & Price Target

CryoPort is a trusted logistics company in the life sciences industry, with a strong track record of providing temperature-controlled supply chain solutions for the cell and gene therapy market. The company's expansion into new facilities in China and Europe, along with its innovative new product offerings, position it well for continued growth and wallet share expansion in the coming years. The company's revenue beat and positive EBITDA in the second quarter of 2026, as well as its strong pipeline and supportive market dynamics, make it an attractive investment opportunity. However, risks such as clinical trial success and funding fluctuations, as well as external factors like COVID-19, should be carefully monitored. With a conservative margin outlook, CryoPort's growth potential is underestimated compared to its peers, making it a potential undervalued play in the logistics sector.

CryoPort is currently experiencing strong revenue growth driven by the post-REMS wave in its services segment; however, its margins are expected to remain negative until at least FY28 due to high fixed costs. Even with a potential margin improvement to 30%, CryoPort may only reach consistent EBITDA margins of 15.5% in 2028, which is still lower than its bioprocessing peers' margins of 17% to 30%. With a current valuation of 14x FY28E EV/EBITDA, we believe CryoPort is overvalued and forecast it will only reach a valuation closer to its peers at a multiple of 16.5x FY28 EBITDA, resulting in an outlook for negative stock performance.